Drug Trial Radar · NCT05800873
Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
May 15, 2023
Primary completion
Jul 27, 2026
Study completion Jul 27, 2026
Sponsor
- Lead sponsor
- Everest Medicines (China) Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases. The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The first targeted disease is primary membranous nephropathy.
Conditions
- Primary Membranous Nephropathy
Interventions
EVER001Drug
A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
EVER001Drug
A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
Primary outcomes
What the sponsor says the trial is designed to measure.
- adverse eventsTime frame: 104 weeks.
- clinical laboratory assessments.Time frame: 104 weeks.
- vital signs.Time frame: 104 weeks.
- physical examinationTime frame: 104 weeks
- ECG.Time frame: 104 weeks.
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China
The Second Xiangya Hospital Of Central South University
Changsha, Changsha, China
The First Affiliated Hospital of PLA Army Medical University
Chongqing, Chongqing Municipality, China
The Third Affiliated Hospital,Sun Yat Sen University
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Harbin, China
Xiangya Third Hospital, Central South University
Changsha, Hunan, China
The First Affiliated Hospital of Baotou Medical College
Baotou, Inner Mongolia, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Medical college of Xi'an Jiaotong University
Xian, Shanxi, China
Sichuan Province People's Hospital
Chengdu, Sichuan, China
Second Hospital of Shanxi Medical University
Shanxi, Taiyuan, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
The first affliated hospital of NingBo university
Ningbo, Zhejiang, China
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.